132 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
, British Columbia, V6C 0A3.
XORTX is a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive … company, focused on developing and potentially commercializing innovative therapies to treat progressive kidney disease modulated by aberrant purine
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
innovative features with our product candidates, even if our 505(b)(2) application does not identify the previously-approved drug product as a listed drug … and of oxypurinol, a uric acid lowering agent that works by effectively inhibiting xanthine oxidase. We are developing innovative product candidates
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
focused on developing innovative therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease … .
BUSINESS OVERVIEW
XORTX is a late-stage clinical pharmaceutical company, focused on developing innovative and potentially commercializing innovative
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
, Vancouver, British Columbia, V6C 0A3.
XORTX is a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive … pharmaceutical company, focused on developing and potentially commercializing innovative therapies to treat progressive kidney disease modulated by aberrant purine
424B3
tg2js46cq8 iu3
13 Jun 24
Prospectus supplement
4:11pm
424B3
is8jafpmsv88
13 Jun 24
Prospectus supplement
4:10pm
424B3
9rqp0est
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.1
s85rgsh hk7
12 Jun 24
Current report (foreign)
7:00am
6-K
EX-99.1
liaaoz9z1qjgi6bivl
4 Jun 24
XORTX to Present at BIO International Convention 2024
8:30am
6-K
EX-99.1
2uea79u3stnmfbqxk
17 May 24
Current report (foreign)
7:00pm
6-K
EX-99.1
l8z7yhg
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.2
iznc13oh8jjj6kamyg
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
mgh6s2e
30 Apr 24
Current report (foreign)
2:58pm
6-K
EX-99.1
13lrkhfhk 0sk
22 Apr 24
XORTX Announces Publication of Key Research in ADPKD
7:00am
6-K
EX-99.1
vnlcii rqwu9z4
8 Apr 24
XORTX Welcomes New Member to the Board of Directors
7:30am
6-K
EX-99.1
ymx6po3 dz
8 Apr 24
XORTX Announces Participation in Spring 2024 Investor Conferences
7:00am
6-K
EX-99.1
fhl0shjfgx7g0cev5tkp
27 Mar 24
XORTX Announces New Clinical Advisory Board Member
7:42am